PHR1021
磷酸克林霉素
Pharmaceutical Secondary Standard; Certified Reference Material
别名:
克林霉素 2-磷酸酯
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H34ClN2O8PS
化学文摘社编号:
分子量:
504.96
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
certified reference material
pharmaceutical secondary standard
质量水平
Agency
traceable to Ph. Eur. C2269000
traceable to USP 1138008
API类
clindamycin
CofA
current certificate can be downloaded
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
-10 to -25°C
SMILES字符串
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O
InChI
1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1
InChI key
UFUVLHLTWXBHGZ-MWBQRTRKSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Clindamycin is a common antibiotic drug generally employed for the treatment of infections caused by gram-positive aerobes and both gram-negative and gram-positive anaerobic pathogens.
Clindamycin is a common antibiotic drug generally employed for the treatment of infections caused by gram-positive aerobes and both gram-negative and gram-positive anaerobic pathogens.
应用
Clindamycin Phosphate may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography and potentiometry techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
生化/生理作用
Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.
分析说明
These secondary standards offer multi-traceability to the USP and EP (PhEur) primary standards, where they are available.
其他说明
Antibacterial and antiprotozoal antibiotic of the licosamide class.
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAC4009 in the slot below. This is an example certificate only and may not be the lot that you receive.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
涉药品监管产品
此项目有
High-performance liquid chromatography of clindamycin antibiotics using tris (bipyridine)-ruthenium (III) chemiluminescence detection
Targove MA and Danielson ND
Journal of Chromatographic Science, 28(10), 505-509 (1990)
Nonisothermal stability assessment of stable pharmaceuticals: testing of a clindamycin phosphate formulation
Kipp JE and Hlavaty JJ
Pharmaceutical Research, 8(5), 570-575 (1991)
Sub-second adsorption for the fast sub-nanomolar monitoring of Clindamycin in its pure and pharmaceutical samples by fast Fourier transformation with the use of continuous cyclic voltammetry at an Au microelectrode in a flowing system
Norouzi P, et al.
Materials Science and Engineering, C, 28(1), 87-93 (2008)
M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持